<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03886935</url>
  </required_header>
  <id_info>
    <org_study_id>201810011837</org_study_id>
    <nct_id>NCT03886935</nct_id>
  </id_info>
  <brief_title>Metabolic Remodeling in Fontan Patients</brief_title>
  <official_title>Metabolic Remodeling in Fontan Patients: a Metabolomics Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biocrates Life Sciences AG, Innsbruck, Austria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tiroler Wissenschaftsförderung</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University Innsbruck</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of metabolic alterations in adult Fontan patients with a dominant left ventricle&#xD;
      with the help of serum examinations (Metabolomics). The aim is to find a tool for the&#xD;
      completion of the (semi-)invasive monitoring of Fontan hemodynamics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who are born with just one single heart chamber need to undergo surgical therapy&#xD;
      allowing the single heart chamber to pump the blood into the systemic circulation and&#xD;
      allowing the blood to flow passively to the lungs (Fontan circulation). Regular ultrasound,&#xD;
      cardiopulmonary exercise testing, and invasive diagnostic tools (catheterization, general&#xD;
      anaesthesia needed) are necessary to early find out cardiac, vascular, or circulatory&#xD;
      impairment. It is still very difficult to diagnose and therapy failure of this Fontan system&#xD;
      early enough.&#xD;
&#xD;
      It is reported that in patients with a failing two-chambered heart, the energy source for the&#xD;
      heart and the body in general switches from the use of lipids to the use of sugar and ketone&#xD;
      bodies. First studies show decreased concentrations of membrane lipids in Fontan patients&#xD;
      with a left dominant ventricle, and the energy metabolism has not been focused yet in those&#xD;
      patients.&#xD;
&#xD;
      The investigators hypothesize that there are differences in the pattern of the structural&#xD;
      metabolism in adult Fontan patients with a left-dominant vs. a right-dominant ventricle.&#xD;
      Furthermore the investigators hypothesize that there are alterations in the energy metabolism&#xD;
      in adult Fontan patients in comparison to healthy two-chambered controls, and that those&#xD;
      alterations correlate with the grade of impairment of cardiopulmonary function.&#xD;
&#xD;
      With the help of a special biochemical examination (mass spectrometry-based Metabolomics&#xD;
      study) blood of Fontan patients will be analyzed, and the results will be correlated with the&#xD;
      results of ultrasound and cardiopulmonary exercise testing. The aim of this study is to&#xD;
      establish sensitive blood markers indicating cardiac, vascular, circulatory or further organ&#xD;
      dysfunction in Fontan patients. This should allow optimal Fontan system monitoring with an&#xD;
      optimal timing of an additional invasive diagnostic catheterization and of nutritional,&#xD;
      medical or interventional therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Actual">January 1, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolism of lipids</measure>
    <time_frame>blood sampling at one single point of time (baseline/day 1) in the context of a planned patient presentation at the pediatric cardiology outpatient clinic (without assessment of changes)</time_frame>
    <description>Measurement of the serum concentration of the extended metabolism of lipids using the technique of Metabolomics (AbsoluteIDQ p180 kit, Biocrates Life Sciences AG, Innsbruck, Austria)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolism of amino acids and related compounds</measure>
    <time_frame>blood sampling at one single point of time (baseline/day 1) in the context of a planned patient presentation at the pediatric cardiology outpatient clinic (without assessment of changes)</time_frame>
    <description>Measurement of the serum concentration of the extended metabolism of lamino acids using the technique of Metabolomics (AbsoluteIDQ p180 kit, Biocrates Life Sciences AG, Innsbruck, Austria)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolism of carbohydrates</measure>
    <time_frame>blood sampling at one single point of time (baseline/day 1) in the context of a planned patient presentation at the pediatric cardiology outpatient clinic (without assessment of changes)</time_frame>
    <description>Measurement of the serum concentration of the extended metabolism of carbohydrates using the technique of Metabolomics (AbsoluteIDQ p180 kit, Biocrates Life Sciences AG, Innsbruck, Austria)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolism of ketone bodies</measure>
    <time_frame>blood sampling at one single point of time (baseline/day 1) in the context of a planned patient presentation at the pediatric cardiology outpatient clinic (without assessment of changes)</time_frame>
    <description>Measurement of the serum concentration of ketone bodies using the technique of Metabolomics (AbsoluteIDQ p180 kit, Biocrates Life Sciences AG, Innsbruck, Austria)</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Congenital Heart Disease</condition>
  <condition>Metabolism Disorder</condition>
  <arm_group>
    <arm_group_label>Fontan patients</arm_group_label>
    <description>The serum of Fontan patients is compared to the serum of healthy biventricular controls (Metabolomics)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy biventricular controls</arm_group_label>
    <description>The serum of Fontan patients is compared to the serum of healthy biventricular controls (Metabolomics)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Metabolomics</intervention_name>
    <arm_group_label>Fontan patients</arm_group_label>
    <arm_group_label>Healthy biventricular controls</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients ≥ 18 years with a Fontan circulation with a dominant left ventricle.&#xD;
&#xD;
        Controls: age- and sex-matched healthy biventricular controls ≥ 18 years&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Fontan circulation (right systemic ventricle), biventricular heart with heart failure&#xD;
             resp.&#xD;
&#xD;
          -  ≥ 18 years&#xD;
&#xD;
          -  Written informed consent of patients&#xD;
&#xD;
          -  8 hours fasting period before blood sample&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Intake of medication directly affecting metabolic (e.g. metabolism of lipids (statine)) or&#xD;
        hemodynamic state (e.g. beta-blockers, sildenafil) (other than angiotensin converting&#xD;
        enzyme (ACE)-inhibitors and anticoagulation therapy)&#xD;
&#xD;
          -  Cachectic disease&#xD;
&#xD;
          -  Non-congestive hepatic or renal dysfunction&#xD;
&#xD;
          -  (Inherited) metabolic disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniela Karall, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Innsbruck</affiliation>
  </overall_official>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>March 11, 2019</study_first_submitted>
  <study_first_submitted_qc>March 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2019</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Participant data will be available only to the head of the study (Dr. Miriam Michel) (Excel- and SPSS-files)</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

